USE OF CLOSED SYSTEM TRANSFER DEVICES WITH INVESTIGATIONAL DRUG PRODUCTS
6ER-033
PEMBROLIZUMAB AND ATEZOLIZUMAB AS POSSIBLE EQUIVALENT FIRST-LINE THERAPEUTIC ALTERNATIVES IN PDL1-EXPRESSING TRIPLE-NEGATIVE BREAST CANCER
6ER-032
HOW CAN DUTCH UNIVERSITY HOSPITALS CONTRIBUTE TO AFFORDABLE MEDICINES AND COST CONTAINMENT OF TOTAL HOSPITAL DRUG EXPENDITURE: A DELPHI STUDY
6ER-031
KWOLEDGE ABOUT HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSMISSION IN PEOPLE LIVING WITH HIV IN ANTIRETROVIRAL THERAPY
6ER-030
USING A PHARMACIST-LED ASTHMA SERVICE TO ASSESS THE CONCORDANCE BETWEEN PATIENT-REPORTED ICS ADHERENCE AND OBJECTIVE E-MONITORING OF ICS THERAPY
6ER-029
EYE DROPS OF INTERFERON ALPHA-2B TO TREAT OCULAR PATHOLOGIES
6ER-028
ASSESSMENT OF SYMPTOMS AND SIGNS SEVERITY IN PSORIASIS PATIENTS
6ER-027
ASSESSMENT OF ATTITUDES AND PERCEIVED SKILLFULNESS OF PHARMACY STUDENTS IN CARING FOR UNDERSERVED POPULATIONS
6ER-026
SPECTRUM OF HEART FAILURE IN 16 SUB-SAHARAN AFRICAN COUNTRIES: TREATMENTS AND IN-HOSPITAL OUTCOME
6ER-025
EFECTIVENESS AND SAFETY OF 20% AUTOLOGOUS SERUM EYE DROPS IN PATIENTS WITH CORNEAL SURFACE PATHOLOGIES
6ER-024
COMPARISON OF REDUCTIONS IN MONTHLY MIGRAINE DAYS BETWEEN NEW SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS (GEPANTS) AND MONOCLONAL ANTIBODIES TARGETING CGRP/CGRP RECEPTOR
6ER-023
THE ASSOCIATION BETWEEN NADROPARIN DOSE AND ANTI-XA LEVELS IN RENAL INSUFFICIENCY: A MULTICENTER STUDY
6ER-022
CLINICAL IMPACT OF THE USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF COVID-19 IN INTERMEDIATE RESPIRATORY CARE UNITS
6ER-021
RETROSPECTIVE OF DRUG INNOVATION DURING THE SARS-Cov2 PANDEMIC : DEVELOPMENT OF A GAME-BASED TRAINING
6ER-020
PRESCRIPTION AND USE OF LIPOSOMAL AMPHOTERICIN B DURING THE COVID-19 PANDEMIC
